Clodi, Martin

PONTIAC (NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease)

Huelsmann, M., Neuhold, S., Resl, M., Strunk, G., Brath, H., Francesconi, C., Adlbrecht, C., Prager, R., Luger, A., Pacher, R., et al. (2013) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 385

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis

Agarwal, R., Tu, W., Farjat, A. E., Farag, Y. M. K., Toto, R., Kaul, S., Lawatscheck, R., Rohwedder, K., Ruilope, L. M., Rossing, P., et al. (2023) · Annals of Internal Medicine

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 109

β-cell activity and hepatic insulin extraction following dexamethasone administration in healthy subjects

Kautzky-Willer, A., Thomaseth, K., Clodi, M., Ludvik, B., Waldhäusl, W., Prager, R., & Pacini, G. (1996) · Metabolism

Pancreatic function and diabetesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 35

Systemic administration of oxytocin reduces basal and lipopolysaccharide-induced ghrelin levels in healthy men

Vila, G., Riedl, M., Resl, M., van der Lely, A. J., Hofland, L. J., Clodi, M., & Luger, A. (2009) · Journal of Endocrinology

Regulation of Appetite and ObesityNeuropeptides and Animal Physiology

Cited by 31